Manchester BIOGEL, which is part of the Deepbridge Life Sciences EIS portfolio, has expanded its team by adding two new members, both of whom will focus on the production of PeptiGels® and lab operation.
This comes as good news for Deepbridge following our agreement of an EIS funding round earlier this year of £1.54 million, which follows an initial seed funding round in 2016 of £150,000.
Read more about the appointments, here.
About Manchester BIOGEL
Manchester BIOGEL develops formulated ready-to-use and easy-to-handle hydrogels that are primarily used in medical research laboratories. Supporting scientists to use bioprinting, liquid handling and 3D cell culture to develop new technologies that aim to improve patient lives.